XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

XOMA Royalty Corporation announced quarterly preferred stock dividends for Series A and Series B preferred shareholders, with Series A receiving $0.53906 per share and Series B receiving $0.52344 per depositary share, payable on July 15, 2026. The company also announced the redemption of all outstanding preferred stock at $25.00 per share on July 14, 2026, in connection with its pending merger with Ligand Pharmaceuticals through Flex Merger Sub, Inc. Additionally, the record date for CVR distribution to common stockholders has been set for July 13, 2026.

06/12/2026, 4:05 PM • Benzinga

Ligand Announces 2026 Investor Day in New York City

Ligand Pharmaceuticals announced it will host an Investor Day in New York City on December 8, 2026, featuring presentations from senior management on the company's strategy, investment activity, royalty portfolio, and long-term financial outlook. A live webcast will be available through the company's Investor Relations website.

06/10/2026, 7:00 AM • GlobeNewswire

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals, sold 5,000 shares worth approximately $1.14 million on June 1, 2026, through the exercise and immediate disposition of stock options. Post-transaction, Reardon retains 41,382 shares and 39,444 employee stock options. The analyst views this as income supplementation rather than a loss of confidence, noting Ligand's strong 123.61% one-year return and growing royalty revenue (up 56% YoY in Q1), though Captisol sales declined.

06/07/2026, 8:28 AM • The Motley Fool

Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing

Investment fund Villere St Denis J & Co LLC completely exited its position in Euronet Worldwide, selling 244,878 shares worth approximately $17.53 million in Q1 2026. The liquidation represents a full exit from a position that previously comprised 1.9% of the fund's assets under management. Euronet shares have declined 25.4% over the past year, underperforming the S&P 500 significantly.

05/04/2026, 1:25 PM • The Motley Fool

XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm

The Schall Law Firm is investigating potential breaches of fiduciary duty by XOMA Royalty Corporation's board and management regarding the company's $739 million acquisition by Ligand Pharmaceuticals. Shareholders are invited to participate in the investigation.

04/28/2026, 5:40 PM • GlobeNewswire

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Ligand Pharmaceuticals announced the acquisition of XOMA Royalty Corporation for $739 million ($39.00 per share in cash). The deal is expected to be immediately accretive to adjusted EPS and increases Ligand's 2026 guidance to $8.50-$9.50 per share, with an additional $1.50 per share contribution expected in 2027. The acquisition expands Ligand's royalty portfolio and strengthens its position as a leading biopharma royalty aggregator.

04/27/2026, 1:18 PM • Benzinga

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of XOMA Royalty Corporation (NASDAQ: XOMA)

Monteverde & Associates PC announced investigations into multiple companies involved in M&A transactions, including XOMA Royalty Corporation's proposed sale to Ligand Pharmaceuticals at $39.00 per share in cash. The firm is examining whether the deal terms are fair to shareholders.

04/27/2026, 10:58 AM • GlobeNewswire

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

Ligand Pharmaceuticals announced it will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. The acquisition expands Ligand's royalty portfolio to over 200 assets and adds seven commercial products. Ligand raised its 2026 adjusted EPS guidance to $8.50-$9.50 and expects the transaction to be accretive by $1.50 per share in 2027. The deal is expected to close in Q3 2026.

04/27/2026, 7:00 AM • Benzinga

Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know

Ligand Pharmaceuticals CFO Octavio Espinoza sold 3,057 shares worth $688,000 on March 11, 2026, representing 12.70% of his direct holdings. The sale was executed under a prearranged 10b5-1 plan and appears to be a structured liquidity event rather than a red flag. Despite the insider sale, Ligand's fundamentals remain strong with 2025 revenue reaching $268.1 million (60% increase) and net income of $124.5 million, with management forecasting up to $285 million in revenue for 2026.

03/27/2026, 7:20 PM • The Motley Fool

Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst

Bank of America Securities initiated coverage of Ligand Pharmaceuticals with a Buy rating and $244 price target, highlighting the biopharmaceutical royalty aggregator's differentiated business model, strong management, and attractive growth prospects. The company beat Q4 earnings expectations with $2.02 EPS versus $1.56 consensus and $59.7M in sales versus $55.6M estimate, while maintaining fiscal 2026 guidance of $8.00-$9.00 EPS and $245-$285M in sales.

03/11/2026, 2:11 PM • Benzinga

This $38.8 Million Vicor Bet Is Getting Bigger Amid a 200% Stock Surge

Ashford Capital Management increased its stake in Vicor by 128,664 shares worth $10.94 million in Q4 2025, bringing its total position to $38.78 million (4.32% of assets). The investment comes as Vicor stock has surged 213% over the past year, driven by strong Q3 results showing 18.5% revenue growth and 57.5% gross margins. The fund's confidence suggests belief in structural demand for Vicor's high-performance power conversion technology in AI and data center infrastructure.

02/17/2026, 10:25 AM • The Motley Fool

What Investors Should Know as One Fund Sells $11 Million of Cavco Industries Stock

Ashford Capital Management sold 19,607 shares of Cavco Industries (CVCO) worth approximately $11.11 million in Q4 2025, reducing its position from 3.1% to 1.87% of fund assets. The sale appears to be a capital reallocation rather than a loss of conviction, as Cavco's fundamentals remain solid with Q3 revenue up 11.3% year-over-year, though the stock has underperformed the S&P 500 by 1.5 percentage points over the past year.

02/17/2026, 10:06 AM • The Motley Fool

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.

12/09/2025, 7:00 AM • GlobeNewswire

Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

Pelthos Therapeutics signed an agreement with a major Pharmacy Benefit Manager to expand patient access to ZELSUVMI, its FDA-approved topical gel for treating molluscum contagiosum, which affects an estimated 16.7 million people annually.

12/04/2025, 7:00 AM • GlobeNewswire

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

SQ Innovation received FDA approval for Lasix® ONYU, an at-home subcutaneous treatment for edema in heart failure patients, utilizing Ligand's Captisol technology to create a novel high-concentration furosemide formulation.

10/09/2025, 7:00 AM • GlobeNewswire